Allstate Corp Sage Therapeutics, Inc. Transaction History

Allstate Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $157,537 - $224,488	-3,913 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $12,787 - $18,474	-233 Reduced 5.62%	3,913 $222,000
Q1 2021 May 14, 2021	SELL	$70.65 - $96.76 $1,695 - $2,322	-24 Reduced 0.58%	4,146 $310,000
Q4 2020 Feb 12, 2021	BUY	$58.41 - $89.06 $243,569 - $371,380	4,170 New	4,170 $361,000
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $101,282 - $260,477	-1,683 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $347,217 - $470,151	-2,475 Reduced 59.52%	1,683 $236,000
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $656,340 - $761,288	4,158 New	4,158 $761,000

218

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Allstate Corp, based on Form 13F filings with the SEC.

Stay updated on Allstate Corp with notifications on news.